I guess wellington also thinks ARRY is undervalues , otherwise they would disclose such a large holding. Its true there is no way to know what the "true" valuation of any developmental stage biotech is. However if either the AZN or NVS MEK inhibitors show any kind of usefullness we should be going quickly to 600-800 mil mktcap (judging by similar bios) that would get us to around 10. We should hopefully be getting news on AZNs compound by ASCO (hopefully) they have said that it will be this year. you need paitence with ARRY but alot of things can go right here. My opinion.
We do suck on this board - we know nothing about valuation - so we'll rely on Barclay's $10 figure where none of even can read the report. I bet this stock sees $2.50 before it ever sees $3.25. $10 - maybe with a reverse stock split.
we are a bunch of dumbo's. i bet that the person who posted the Barclay's recommendation of $10/share did NOT even have access to the Barclay's report. We all deserve to lose our butts as we do no research or valuation. Basically, we all suck. That's why we make free posts on the Yahoo board.